Emergency treatment for exposure to Ebola virus: The need to fast-track promising vaccines

JAMA - Journal of the American Medical Association

Volumn 313, Issue 12, 2014, Pages 1221-1222

  Geisbert, Thomas W ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BRINCIDOFOVIR; EBOLA VACCINE; FAVIPIRAVIR; IMMUNOGLOBULIN G; VIRUS GLYCOPROTEIN;

ADAPTIVE IMMUNITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EDITORIAL; EMERGENCY TREATMENT; EPIDEMIC; FEVER; GERMANY; HEALTH CARE PERSONNEL; HUMAN; INFECTION CONTROL; INFORMED CONSENT; INNATE IMMUNITY; LICENCE; NEEDLESTICK INJURY; NONHUMAN; PATIENT ATTITUDE; PHASE 1 CLINICAL TRIAL (TOPIC); POST EXPOSURE PROPHYLAXIS; PRIMATE; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; PUBLIC HEALTH SERVICE; SIERRA LEONE; VESICULOVIRUS; VIRUS INHIBITION; VIRUS REPLICATION; COMPLICATION; HEMORRHAGIC FEVER, EBOLA; MALE;

EBOLA VACCINES; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; NEEDLESTICK INJURIES; POST-EXPOSURE PROPHYLAXIS;

EID: 84925430920     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.2057     Document Type: Editorial

References (10)

1. th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013:923-956.
2. World Health Organization. Ebola situation report. http://apps.who.int/ebola/en/ebola -situation-report/situation-reports/ebola-situation -report-18-february-2015. Accessed February 25, 2015.
3. Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines. 2014;13(4):521-531.
4. Lai L, Davey R, Beck A, et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA. doi:10.1001/jama.2015.1995.
5. Jones SM, Feldmann H, Ströher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11(7):786-790.
6. Günther S, Feldmann H, Geisbert TW, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis. 2011;204(suppl 3):S785-S790.
7. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007;3(1):e2.
8. Qiu X,Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514(7520):47-53.
9. Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375(9729):1896-1905.
10. Hirschberg R,Ward LA, Kilgore N, et al. Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop. Viruses. 2014;6(7): 2673-2697.